Financials data is unavailable for this security.
View more
Year on year Guizhou Sanli Pharmaceutical Co Ltd grew revenues 36.10% from 1.20bn to 1.63bn while net income improved 45.42% from 201.28m to 292.70m.
| Gross margin | 70.14% |
|---|---|
| Net profit margin | 16.27% |
| Operating margin | 18.66% |
| Return on assets | 12.76% |
|---|---|
| Return on equity | 21.80% |
| Return on investment | 19.35% |
More ▼
Cash flow in CNYView more
In 2023, Guizhou Sanli Pharmaceutical Co Ltd did not generate a significant amount of cash. Cash Flow from Financing totalled 337.63m or 20.65% of revenues. In addition the company generated 276.70m in cash from operations while cash used for investing totalled 613.78m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 3.72 |
|---|---|
| Tangible book value per share | 1.82 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.86 |
|---|---|
| Quick ratio | 1.52 |
| Total debt/total equity | 0.3854 |
|---|---|
| Total debt/total capital | 0.2486 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 100.00% and 43.68%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.60% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 26.44% |
| EPS growth(5 years) | 18.69 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 24.57 |
More ▼
